

Report from Extraordinary General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, February 5, 2026. Affibody Medical AB (publ) today held an Extraordinary General Meeting. The following resolutions were adopted.

The General Meeting resolved on the introduction of an employee stock option program 2026/2031:1. The program comprises not more than 1,005,000 stock options. Each employee stock option shall entitle the holder to acquire one (1) new share in the company at an exercise price of SEK 28.60. Offers of employee stock options shall be decided by the Board of Directors. The stock options may, unless the Board of Directors resolves on a right of subscription prior thereto, be exercised no earlier than three (3) years after the participant signed the option agreement relating to the employee stock options, and no later than 14 February 2031.

Further, the General Meeting resolved on the introduction of a stock option program 2026/2031:2 for certain members of the Board of Directors. The program comprises not more than 295,000 stock options. Each stock option shall entitle the holder to acquire one (1) new share in the company at an exercise price of SEK 28.60. The stock options may be exercised no earlier than three (3) years after the participant signed the option agreement relating to the stock options, and no later than 14 February 2031.

Issued stock options pursuant to these programs do not constitute securities and may not be transferred, pledged, or otherwise disposed of by the holder. The stock options are, respectively, tied to the participant's employment and engagement as director in the company.

To enable the delivery of shares under the above programs, it was further resolved on directed issues of a total of no more than 1,625,000 warrants. It was finally resolved to authorize the company to transfer warrants or shares to participants in the programs or otherwise dispose of the warrants to fulfill the company's obligations arising from the stock option programs.

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody[®] molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody's lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.

The Affibody[®] platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Contacts (Affibody)

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Contacts (Media)

Richard Hayhurst, 59° North Communications, richard.hayhurst@59north.bio, +44 (0) 7711 8215727

Attachments

[Report from Extraordinary General Meeting in Affibody Medical AB \(publ\)](#)